Semax
Semax (Heptapeptide ACTH Analogue)
Semax is a synthetic heptapeptide analogue of ACTH(4-7), developed in Russia and approved there for clinical use in stroke and cognitive decline. It is studied for BDNF upregulation, neuroprotection, cognitive enhancement, and stroke recovery. Intranasal delivery allows direct nose-to-brain transport, bypassing the blood-brain barrier.
Mechanism of Action
Semax's primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) — a neurotrophin critical for neuronal survival, synaptic plasticity, and neurogenesis. In animal models, Semax increases BDNF mRNA expression in the cortex and hippocampus within hours of administration.
Semax also modulates the serotonergic and dopaminergic systems, which partially explains its reported effects on mood, motivation, and stress resilience. Animal studies demonstrate reduced anxiety-like behaviour and enhanced spatial memory in rodent cognition models.
Intranasal Semax reaches CNS tissue via olfactory nerve transport and direct mucosal absorption. Despite a short plasma half-life, CNS retention is prolonged — contributing to effects lasting several hours beyond the initial absorption window.
Research Evidence
Semax has been investigated in Russian clinical research since the 1980s. It has been approved in Russia as a drug for stroke, TBI, and cognitive decline. Western research interest has grown, but large RCTs meeting current Western regulatory standards are limited.
Semax Increases BDNF Expression and Protects Against Ischaemic Brain Injury
Intranasal Semax significantly elevated BDNF mRNA in rat cerebral cortex and reduced infarct volume in a thread-occlusion ischaemia model, confirming neuroprotective mechanism via neurotrophic pathway upregulation.
Clinical Efficacy of Semax in Acute Ischaemic Stroke
Randomised trial in acute stroke patients showed Semax intranasal significantly improved neurological recovery scores versus placebo at 10-day and 6-month follow-ups, with favourable tolerability profile.
Typical Research Protocol
N-Acetyl Semax (NA-Semax) is a stabilised form with improved potency and bioavailability. Cycles are typically kept short (2–4 weeks) with 2-week breaks to prevent adaptation.
Safety Profile
Reported Side Effects
- Nasal irritation
- Mild stimulation/anxiety (dose-dependent)
- Headache (initial)
- Temporary appetite change
Contraindications
- Active psychiatric conditions (bipolar, schizophrenia)
- Epilepsy/seizure disorders
- Pregnancy
- Known ACTH pathway hypersensitivity
Published Research
208 indexed PubMed papers reference Semax. The 20 most recent are listed below.
-
Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.
PMID 42752426 Open on PubMed →
- Quantitative MRI Pharmacokinetic Modeling and MALDI Mass Spectrometry Imaging Biodistribution of a pH Mapping MRI Contrast Agent.
- [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome].
- Multi-Layer Magnetic Shields Based on Fe-Based Nanocrystalline and Co-Based Amorphous Ribbons.
- Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study.
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.
- Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats).
- The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.
- Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
- Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.
- Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing.
- ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.
- Robust Multifunctional Films with Excellent EMI Shielding, Anti-Peeling, and Joule Heating Performances Enabled by an Encapsulated Highly Conductive Fabric Strategy.
- Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.
- Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides.
- Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period.
- Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects.
Common Research Stacks
Frequently Asked Questions
Is Semax legal?
Semax is not scheduled as a controlled substance in most Western countries and is not on the FDA's list of approved or prohibited drugs. It exists in a legal grey area — not approved for human use, not explicitly prohibited. It is approved and registered as a pharmaceutical drug in Russia. Verify current status in your jurisdiction before obtaining.
What does Semax feel like?
User reports (informal) commonly describe increased mental clarity, motivation, and processing speed within 30–60 minutes of intranasal administration. Some note mild stimulatory effects similar to low-dose caffeine. Effects tend to be subtle and cumulative rather than immediately dramatic — most notable cognitive benefits emerge after 5–10 days of consistent use.
What is the difference between Semax and NA-Semax?
NA-Semax (N-Acetyl Semax) is an acetylated form of Semax with improved lipophilicity, stability in nasal mucosa, and greater potency. The N-acetyl modification increases CNS penetration via the olfactory route. NA-Semax Amidate is a further modification combining acetylation and C-terminal amidation for maximum stability and potency. Lower doses of NA-Semax (100–200 mcg) are typically used compared to standard Semax (400–600 mcg).
Can Semax be used for ADHD or focus disorders?
Semax's BDNF upregulation and dopaminergic modulation make it of research interest for attention and executive function. Informal reports describe improved focus and reduced mental fatigue that some find relevant to ADHD symptoms. However, there are no controlled trials in ADHD populations specifically, and it should not be considered a replacement for evidence-based ADHD treatments.
How should Semax be stored?
Reconstituted Semax nasal spray should be stored refrigerated (2–8°C) and used within 4–6 weeks. Lyophilised powder remains stable at room temperature for months but should be refrigerated for long-term storage. Light exposure degrades the peptide — use dark or amber glass vials and minimise UV exposure during handling.
Key Research References
- Mendzheritsky AM et al. (2001). Neuroprotective effects of Semax in cerebral ischaemia. Neurosci Lett.
- Kaplan AY et al. (1996). Semax effects on EEG activity in humans. Neurosci Behav Physiol.
Explore more Cognitive research compounds
Browse Cognitive →